Alperpriv - instructions for use, doses, side effects, contraindications

Alerpriv (loratadine) - blocker of H1-histamine receptors (long-acting). Inhibits the release of histamine and leukotriene C4 from mast cells. Prevents development and facilitates the course of allergic reactions. It has anti-allergic, antipruritic and antiexcudative action. Reduces the permeability of capillaries, prevents the development of edema of tissues, relieves spasms of smooth muscles. The antiallergic effect develops in 30 minutes, reaches a maximum in 8-12 hours and lasts for 24 hours. It does not affect the central nervous system and does not cause addiction (because it does not penetrate the blood-brain barrier).

Pharmacokinetics:

Quickly and completely absorbed in the gastrointestinal tract. Time to reach the maximum concentration - 1,3-2,5 h; the intake of food slows it down for 1 hour. The maximum concentration in the elderly increases by 50%, with alcoholic damage to the liver in accordance with the increased severity of the disease. Connection with proteins plasma - 97%. Metabolized in the liver with the formation of an active metabolite of descarbon ethoxyloratadine with the participation of cytochrome P450 isoenzymes CYP3A4 and to a lesser extent CYP2D6. The equilibrium concentration of loratadine and metabolite in plasma is reached on the 5th day of administration. Does not penetrate the blood-brain barrier. The half-life of loratadine is 3-20 hours (an average of 8.4), the active metabolite is 8.8-92 hours (an average of 28 hours); in elderly patients, respectively, 6.7-37 hours (an average of 18.2 hours) and 11-38 hours (17.5 hours). In alcoholic liver damage, the half-life increases with increasing severity of the disease. It is excreted in the night and with bile. In patients with chronic renal failure and during hemodialysis, the pharmacokinetics practically does not change.

Indications:

Seasonal and all-the-year-round allergic rhinitis, conjunctivitis, hay fever, urticaria (including chronic idiopathic), Quincke's edema, allergic itching dermatoses; pseudoallergic reactions, allergic reactions to insect bites, itching of various etiologies.

Contraindications:

Hypersensitivity. Pregnancy, lactation, children under 2 years.

Hereditary intolerance to galactose, fructose, Lappease lactase deficiency or glucose-galactose malabsorption syndrome.

Carefully:Liver failure.

Dosing and Administration:

Inside.

Adults and children over 12 years: 10 mg (1 tablet) 1 time per day. The daily dose of 10 mg. Children from 2 to 12 years, 5 mg (1/2 tablets) 1 time per day. The daily dose of 5 mg. Children with a body weight of more than 30 kg - 10 mg of the drug once a day. The daily dose is 10 mg.

Side effects:

The undesirable phenomena listed below, when using loratadine were found with the frequency ≥2% and approximately at the same frequency as with the placebo ("dummies").

In adults: headache, fatigue, dry mouth, drowsiness, gastrointestinal disorders (nausea, gastritis), as well as allergic reactions in the form of rashes. In addition, there were rare reports of anaphylaxis, alopecia, impaired liver function, palpitation, tachycardia.

Have a detectiveth rarely: headache, nervousness, sedation.

Overdose:

Symptoms: drowsiness, tachycardia, headache. In case of overdose, see a doctor.

Treatment: induction of vomiting, gastric lavage, reception of activated carbon.

Interaction:

Ethanol reduces the effectiveness of loratadine.

Erythromycin, cimetidine, ketoconazole, when combined with loratadine increase the concentration of loratadine in blood plasma,without causing clinical manifestations and without affecting the ECG.

Inductors of microsomal oxidation (phenytoin, barbiturates, zixorin, rifampicin, phenylbutazone, tricyclic antidepressants) reduce the effectiveness of loratadine.

Special instructions:

The drug should be discontinued no less than two days before the skin allergic tests are performed, since the drug Alerpriv® can influence their results.

The drug Alerpriv® is not excreted in hemodialysis.

Effect on the ability to drive transp. cf. and fur:

During the treatment period, it is necessary to refrain from engaging in potentially dangerous activities that require a high concentration of attention and speed of psychomotor reactions.

Form release / dosage:Tablets of 10 mg.

Packaging:

For 10 tablets in a blister of PVC / aluminum. For 1 or 3 blisters in a cardboard box with instructions for use.

"In Balk": 100 and 1000 tablets in a plastic container.

Storage conditions:

In dry, protected from light, out of reach of children, at a temperature of no higher than 25 ° C.

Shelf life:

2 years. Do not use after the time specified on the package.

Terms of leave from pharmacies:Without recipe

Registration number:P N 016079/01

Date of registration:05.02.2010

Expiration Date:Unlimited

The owner of the registration certificate:Kimika Montpellier, SA, Bago Group CompanyKimika Montpellier, SA, Bago Group Company Argentina

Manufacturer: & nbsp

QUIMICA MONTPELLIER, S.A. Argentina

Representation: & nbspBBC FARMA BV BBC FARMA BV Netherlands

Information update date: & nbsp06.07.2017

Illustrated instructions

Instructions

Alerpriv® (Alerpriv)